S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Hot Potato: Lamb Weston Stock Confirms a Top 
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Hot Potato: Lamb Weston Stock Confirms a Top 
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Hot Potato: Lamb Weston Stock Confirms a Top 
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Hot Potato: Lamb Weston Stock Confirms a Top 
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
NASDAQ:BLUE

bluebird bio - BLUE Stock Forecast, Price & News

$6.98
+0.19 (+2.80%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.53
$7.19
50-Day Range
$3.75
$7.31
52-Week Range
$2.87
$25.39
Volume
6.65 million shs
Average Volume
9.49 million shs
Market Capitalization
$538.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

bluebird bio MarketRank™ Forecast

Analyst Rating
Hold
1.91 Rating Score
Upside/​Downside
21.8% Upside
$8.50 Price Target
Short Interest
Bearish
26.06% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.34mentions of bluebird bio in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$213,636 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.25) to ($2.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.50 out of 5 stars

Medical Sector

1009th out of 1,072 stocks

Biological Products, Except Diagnostic Industry

162nd out of 169 stocks

BLUE stock logo

About bluebird bio (NASDAQ:BLUE) Stock

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

BLUE Stock News Headlines

bluebird bio (NASDAQ:BLUE) Stock Price Up 9.5%
Should You Buy the Dip With Bluebird Bio?
Why Bluebird Bio Stock Is Taking Flight Today
Is This Growth Stock Undervalued?
Do Back-to-Back Approvals Make This Biotech Stock a Buy Now?
2 Small Caps for Growth-Focused Investors
Why Shares of Bluebird Bio Jumped 15.7% on Tuesday
What 5 Analyst Ratings Have To Say About bluebird bio
Bluebird Bio stock falls after FDA approves gene therapy
2 Risky Stocks That Are Running Low on Cash
Bluebird Bio Chief Strategy And Financial Officer Jason Cole To Resign
Cancer Immunotherapy Global Market Report 2022
See More Headlines
Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

BLUE Company Calendar

Last Earnings
8/04/2022
Today
10/06/2022
Next Earnings (Estimated)
11/04/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLUE
Fax
N/A
Employees
518
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.50
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+21.8%
Consensus Rating
Hold
Rating Score (0-4)
1.91
Research Coverage
11 Analysts

Profitability

Net Income
$-819,380,000.00
Net Margins
-2,141.34%
Pretax Margin
-1,828.94%

Debt

Sales & Book Value

Annual Sales
$3.66 million
Book Value
$5.34 per share

Miscellaneous

Free Float
74,885,000
Market Cap
$538.30 million
Optionable
Optionable
Beta
0.97

Key Executives

  • Mr. Andrew ObenshainMr. Andrew Obenshain (Age 47)
    Pres, CEO & Director
    Comp: $842.85k
  • Mr. Jason F. Cole Esq. (Age 49)
    Treasurer, Principal Accounting Officer & Financial Officer and Chief Strategy & Financial Officer
    Comp: $838.97k
  • Mr. Thomas J. Klima (Age 50)
    Chief Commercial Officer & COO
    Comp: $509.7k
  • Ms. Jessica WhittenMs. Jessica Whitten (Age 45)
    VP, Global Controller & Chief Accounting Officer
  • Ms. Helen C. Fu
    Sr. VP, Gen. Counsel & Sec.
  • Ms. Elizabeth Pingpank
    Director of Corp. Communications
  • Sarah Alspach
    Chief Communications Officer
  • Dr. Liviu Niculescu M.D.
    Ph.D., Sr. VP of Global Medical Affairs
  • Ms. Melissa Bonner
    Sr. VP of Research
  • Mr. Richard Colvin M.D.
    Ph.D., Chief Medical Officer













BLUE Stock - Frequently Asked Questions

Should I buy or sell bluebird bio stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 2 sell ratings, 8 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings
or view top-rated stocks.

What is bluebird bio's stock price forecast for 2022?

11 analysts have issued 1 year price targets for bluebird bio's stock. Their BLUE share price forecasts range from $3.00 to $14.00. On average, they anticipate the company's share price to reach $8.50 in the next year. This suggests a possible upside of 21.8% from the stock's current price.
View analysts price targets for BLUE
or view top-rated stocks among Wall Street analysts.

How have BLUE shares performed in 2022?

bluebird bio's stock was trading at $9.99 at the start of the year. Since then, BLUE stock has decreased by 30.1% and is now trading at $6.98.
View the best growth stocks for 2022 here
.

When is bluebird bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our BLUE earnings forecast
.

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) announced its quarterly earnings data on Thursday, August, 4th. The biotechnology company reported ($1.29) earnings per share for the quarter, topping the consensus estimate of ($1.31) by $0.02. The biotechnology company had revenue of $1.52 million for the quarter, compared to analyst estimates of $6.47 million. bluebird bio had a negative trailing twelve-month return on equity of 130.19% and a negative net margin of 2,141.34%.

What is Nick Leschly's approval rating as bluebird bio's CEO?

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

How do I buy shares of bluebird bio?

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $6.98.

How much money does bluebird bio make?

bluebird bio (NASDAQ:BLUE) has a market capitalization of $538.31 million and generates $3.66 million in revenue each year. The biotechnology company earns $-819,380,000.00 in net income (profit) each year or ($8.32) on an earnings per share basis.

How many employees does bluebird bio have?

The company employs 518 workers across the globe.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.bluebirdbio.com. The biotechnology company can be reached via phone at (339) 499-9300 or via email at investor@bluebirdbio.com.

This page (NASDAQ:BLUE) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.